Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tsRNA-3040b agomir
- Development stage
- Preclinical
- Lead developer
- GENEWIZ
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
tsRNA-3040b agomir is a chemically modified, double-stranded RNA oligonucleotide designed to mimic the endogenous transfer RNA-derived small RNA (tsRNA) tsRNA-3040b (specifically tsRNA-Asp-GTC-3040b). Synthesized by GENEWIZ, this research compound is used to investigate the molecular mechanisms of pulmonary hypertension (PH). It functions by promoting the accumulation of R-loops in the genomic DNA of the Trim35 gene, which subsequently inhibits Trim35 transcription. This downregulation triggers the Wnt3a signaling pathway and leads to disordered glycolysis, promoting the proliferation of pulmonary artery endothelial cells (PAECs). Due to its chemical modifications, the agomir exhibits high stability and membrane affinity, making it particularly suitable for in vivo preclinical animal experiments.
- Other names
- tsRNA-3040b mimictsRNA3040b mimictsRNA 3040b mimictsRNA-Asp-GTC-3040b agomirtsRNA-Asp-GTC3040b agomirtsRNA-Asp-GTC 3040b agomirtsRNA-3040btsRNA3040btsRNA 3040b
02
Targets
TRIM35 (Tripartite motif-containing protein 35)
Beyond the preview
Go deeper on tsRNA-3040b agomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tsRNA-3040b agomir.